HC Wainwright reiterated their buy rating on shares of FocalTherics (NASDAQ:FOCL – Free Report) in a report released on Tuesday morning, MarketBeat reports. The brokerage currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for FocalTherics’ Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.47) EPS, FY2028 earnings at ($0.04) EPS, FY2029 earnings at $0.05 EPS and FY2030 earnings at $0.25 EPS.
A number of other analysts have also weighed in on FOCL. Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Piper Sandler restated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. Finally, Mizuho set a $15.00 price objective on FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, FocalTherics presently has an average rating of “Hold” and an average target price of $7.75.
Get Our Latest Stock Report on FocalTherics
FocalTherics Stock Down 1.6%
FocalTherics (NASDAQ:FOCL – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The firm had revenue of $13.20 million for the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 248.00%. Equities research analysts anticipate that FocalTherics will post -0.82 earnings per share for the current year.
Insider Transactions at FocalTherics
In related news, Director Fran Schulz purchased 10,000 shares of FocalTherics stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director directly owned 15,100 shares of the company’s stock, valued at $71,725. This represents a 196.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Joshua Levine purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average cost of $4.75 per share, with a total value of $47,500.00. Following the completion of the purchase, the director owned 45,000 shares of the company’s stock, valued at $213,750. This represents a 28.57% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 116,000 shares of company stock worth $551,000. 10.10% of the stock is owned by corporate insiders.
Institutional Trading of FocalTherics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. SmartHarvest Portfolios LLC purchased a new position in shares of FocalTherics during the 1st quarter worth approximately $38,000. Lido Advisors LLC purchased a new position in shares of FocalTherics in the 1st quarter valued at approximately $40,000. Kovack Advisors Inc. purchased a new position in shares of FocalTherics in the 4th quarter valued at approximately $53,000. Leonteq Securities AG bought a new stake in shares of FocalTherics during the fourth quarter valued at approximately $313,000. Finally, Flax Pond Capital LLC bought a new stake in shares of FocalTherics during the fourth quarter valued at approximately $2,623,000. 62.74% of the stock is currently owned by hedge funds and other institutional investors.
FocalTherics News Summary
Here are the key news stories impacting FocalTherics this week:
- Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $10 price target, substantially above FocalTherics’ recent trading level. The firm also raised its FY2027 EPS forecast to a loss of $0.47 from $0.54, suggesting improved expectations for the company’s operating trajectory. HC Wainwright Reiterates Buy Rating for FocalTherics
- Positive Sentiment: The analyst raised EPS estimates for the third quarter of 2026 and the first three quarters of 2027. Longer-term forecasts call for losses to narrow to $0.04 per share in FY2028, followed by profits of $0.05 in FY2029 and $0.25 in FY2030, indicating expectations for eventual earnings improvement. FocalTherics Analyst Estimates
- Neutral Sentiment: HC Wainwright issued quarterly and annual projections through FY2030, with the current full-year consensus estimate at a loss of $0.78 per share. The forecasts provide a more constructive long-term outlook but also emphasize that FocalTherics remains unprofitable in the near term. FocalTherics Earnings Estimates
- Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to a loss of $0.82 from $0.78 and cut its fourth-quarter 2026 estimate to a loss of $0.20 from $0.15. These near-term downgrades may weigh on sentiment, particularly given FocalTherics’ recent earnings loss and ongoing cash-burn concerns. FocalTherics Revised Earnings Estimates
About FocalTherics
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
Featured Articles
- Five stocks we like better than FocalTherics
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for FocalTherics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FocalTherics and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}
